ClinicalTrials.gg
RecruitingNCT07058519Updated Nov 26, 2025

A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC

A Phase 2 interventional study of Osimertinib-based adaptive treatment and Osimertinib 80 MG in Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC), sponsored by Shanghai Chest Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-26.

Sponsored by Shanghai Chest Hospital · Phase 2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
250
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 43 under way, 8 of them phase 3. osimertinib · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
12th of 90
250 · median 51
Started
2025
with 1 other
Phase 2
46 of 90
12 open now
Primary completion
2029-01
later than 36 of 42 live
Registered
85th of 90
by date

Among the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, this one is the 12th largest by planned enrollment, is one of 2 that started in 2025, is one of 46 in phase 2, reaches primary completion later than 36 of the 42 other live ones, and was the 85th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

20 of the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung are open now, in 7 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About osimertinib

osimertinib: first FDA approval 2015 (TAGRISSO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The goal of this adaptive, interventional study is to assess the efficacy and safety of osimertinib-based adaptive treatment based on ctDNA dynamic monitoring in locally advanced or metastatic EGFRm NSCLC participants with ctDNA EGFRm clearance after osimertinib plus chemotherapy. The main questions it aims to answer are: 1) PFS during adaptive treatment period in Cohort 1 defined as from initiation of Osimertinib in adaptive period to progression per investigator assessment; 2) Time from initiation of osimertinib in adaptive period to first ctDNA EGFRm relapse or death

Read the detailed description

Locally advanced or metastatic EGFR mutation-positive (EGFRm) non-small cell lung cancer (NSCLC) (Stage IIIB, IIIC, IV, or recurrent) has a poor prognosis. The 5-year survival rate for metastatic disease is only 8.9%.

While combination therapy with osimertinib and platinum-pemetrexed chemotherapy, as validated by the FLAURA2 trial, has demonstrated improved progression-free survival (PFS), it also introduces increased toxicity, treatment burden, and reduced quality of life. Notably, a subset of patients-approximately 25-30%-achieves long-term benefit from osimertinib monotherapy alone, highlighting the potential to personalize treatment intensity.

Emerging evidence supports circulating tumor DNA (ctDNA) as a dynamic biomarker for guiding therapy. Analyses from FLAURA2 and other studies have shown that early ctDNA EGFRm clearance strongly correlates with superior PFS and can identify patients who may not require continuous combination therapy. Adaptive strategies based on ctDNA clearance have enabled treatment de-escalation in early-stage and advanced NSCLC settings, maintaining efficacy while reducing toxicity. This trial builds on that rationale, aiming to validate ctDNA-guided adaptive therapy to balance efficacy, safety, and quality of life in EGFRm NSCLC.

03

Conditions studied

  • Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)

Keywords

  • NSCLC
  • EGFRm+
  • Osimertinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated, written form (ICF) prior to any study specific procedures.
  2. Male or female participants aged 18 years old and above.
  3. PS of 0-1.
  4. of at least 3 months at recruitment.
  5. Participants able to collect plasma samples at baseline.
  6. Newly diagnosed, and documented locally advanced or non-squamous NSCLC with sensitizing EGFR mutations positive (either Exon 19 deletion or 21 L858R, confirmed by histology or cytology), and classified as stage IIIB, IIIC, IV or recurrent NSCLC which are not amenable to curative surgery or radiotherapy (per Version 8 of the International Association for the Study of Lung Cancer [IASLC] Staging Manual in Thoracic Oncology).
  7. Detectable EGFRm (Ex19del or L858R) in plasma ctDNA by central Super ARMS PCR testing at the time of screening.
  8. Participants must have untreated advanced NSCLC and intend to receive osimertinib plus chemotherapy as treatment. Prior and neo-adjuvant therapies (chemotherapy, radiotherapy, immunotherapy, biologic therapy, agents), or definitive radiation/chemoradiation with or without regimens including immunotherapy, biologic therapy, investigational agents, are permitted as long as treatment was completed at least 12 months prior to receiving the first dose of study treatment.
  9. Participants with asymptomatic and stable central nervous system (CNS) metastases for at least 2 weeks (for those who received definitive therapy and , a stable neurological status for at least 2 weeks after completion of the treatment is required) will be allowed, including .
  10. At least 1 lesion, not previously irradiated that can be accurately measured at baseline as ≥10 mm in the longest diameter (except lymph nodes, which must have a short axis of ≥15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI), and that is suitable for accurate repeated measurements. If only 1 exists, it is acceptable to be used (as a target lesion) as long as it has not been previously irradiated and as long as it has not been biopsied within 14 days of the baseline tumour assessment scans.
  11. Patients with virus (HBV) are only eligible for inclusion if they meet all the following criteria:

    • Demonstrated absence of virus (HCV) co-infection or history of HCV co-infection
    • Demonstrated absence of (HIV) infection
    • Participants with active HBV infection are eligible if they are:

      • Receiving anti-viral treatment for at least 6 weeks prior to study treatment, HBV DNA is suppressed to \<100 IU/mL and transaminase levels are below (ULN).
    • Participants with a resolved or chronic HBV infection are eligible if they are:

      • Negative for hepatitis B surface antigen (HBsAg) and positive for hepatitis B core antibody [anti-HBc IgG or total anti-HBc Ab]. In addition, patients must be receiving anti-viral prophylaxis for 2-4 weeks prior to study treatment.

    or

    • Positive for HBsAg, but for > 6 months have had transaminases levels below ULN and HBV DNA levels below \<100 IU/mL or below the detectable limit of locally available test kit (i.e., are in an inactive carrier state). In addition, patients must be receiving anti-viral prophylaxis for 2-4 weeks prior to study treatment.
  12. Patients with HIV are only eligible for inclusion if they meet all the following criteria:

    • Demonstrated absence of HBV/ HCV co-infection
    • Undetectable viral RNA load for 6 months
    • of >350 cells/μL
    • No history of AIDS-defining opportunistic infection within the past 12 months
    • Stable for at least 4 weeks on the same anti-HIV medications
  13. Females must be using highly effective measures, and must have a negative pregnancy test prior to start of dosing if of , or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:

    • defined as aged 50 years or more and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments.
    • Women under 50 years old would be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and with LH and FSH levels in the post-menopausal range for the institution.
    • Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.
  14. Male participants must be willing to use barrier contraception.

Exclusion criteria

Exclusion Criteria:

  1. Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required treatment, or any evidence of clinically active ILD.
  2. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the Investigator's opinion makes it undesirable for the participant to participate in the trial or which would jeopardize compliance with the protocol, or active infection (e.g. participants receiving treatment for infection) including and , or active uncontrolled infection. Screening for chronic conditions is not required.
  3. Any of the following cardiac criteria:

    • Mean resting corrected >470 msec, obtained from 3 (ECGs), using the screening clinic ECG machine derived QTc value.
    • Any abnormalities in rhythm, conduction or morphology of resting ECG e.g., complete left bundle branch block, third degree heart block and second degree heart block.
    • Patient with any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as electrolyte abnormalities including:

      • Serum/plasma magnesium* \< LLN
      • Serum/plasma calcium* \< LLN
      • Hypokalaemia* ≥ Grade 2 heart failure, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval and cause Torsade de Pointes.

        • Correction of electrolyte abnormalities should be documented prior to first dose
  4. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:

    • (ANC) \<1.5 × 109/L
    • count \<100 × 109/L
    • \<90 g/L
    • (ALT) >2.5 times the if no demonstrable liver or >5 times ULN in the presence of liver metastases.
    • Aspartate aminotransferase (AST) >2.5 times ULN if no demonstrable liver metastases or >5 times ULN in the presence of liver metastases.
    • Total >1.5 times ULN if no liver metastases or >3 times ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases.
    • Serum Creatinine >1.5 times ULN concurrent with \<50 ml/min (measured or calculated by Cockcroft and Gault equation); confirmation of creatinine clearance is only required when creatinine is >1.5 times ULN.
  5. Any concurrent and/or other active that has required treatment within 2 years of first dose of product (IP).
  6. Any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of starting study treatment with the exception of alopecia and grade 2 prior platinum-therapy related neuropathy.
  7. nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of osimertinib.
  8. Prior treatment with any systemic anti-cancer therapy for advanced NSCLC not amenable to curative surgery or radiation including chemotherapy, biologic therapy, immunotherapy, or any investigational drug. Prior and neo-adjuvant therapies (chemotherapy, radiotherapy, immunotherapy, biologic therapy, investigational agents), or definitive radiation/chemoradiation with or without regimens including immunotherapy, biologic therapies, investigational agents are permitted as long as treatment was completed at least 12 months prior to the development of recurrent disease.
  9. Prior treatment with an EGFR-TKI.
  10. Major surgery within 4 weeks of the first dose of IP. Procedures such as placement of vascular access, via mediastinoscopy or biopsy via video assisted thoracoscopic surgery (VATS) are permitted.
  11. Palliative radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of IP.
  12. Participants currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of cytochrome P450 (CYP) 3A4 (at least 3-week prior). All participants must try to avoid concomitant use of any medications, herbal supplements and/or ingestion of foods with known inducer effects on .
  13. Participation in another clinical study with an investigational product within 5 half-lives of the compound or 3 months whichever is greater prior to Day 1.
  14. History of to active or inactive of Osimertinib or drugs with a similar chemical structure or class to Osimertinib.
  15. for pemetrexed and cisplatin/carboplatin according to local approved label.
  16. Women who are breast-feeding.
  17. Involvement in the planning and/or conduct of the study (applies to both Investigator staff and/or staff at the study site).
  18. Judgment by the Investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions and requirements.
Terms in these criteria, in plain language(36)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Cohort 1 (EGFRm ctDNA Clearance Group)

    EGFRm ctDNA Clearance Group

    Drug: Osimertinib-based adaptive treatment

  • Experimental
    Cohort 2 (ctDNA EGFRm non-clearance group)

    Drug: Osimertinib 80 MG

Interventions

  • DrugOsimertinib-based adaptive treatment

    Participants in Cohort 1 will receive Osimertinib-based adaptive treatment (either Osimertinib monotherapy or Osimertinib plus chemotherapy) depending on ctDNA EGFRm clearance or relapse by ctDNA EGFRm dynamic monitoring, until radiological disease progression (PD) as per RECIST v1.1 or other withdrawal criteria are met.

  • DrugOsimertinibStudies of OsimertinibOsimertinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants in Cohort 2 will receive Osimertinib 80 mg once daily (QD) plus pemetrexed maintenance every 3 weeks (Q3W) until radiological PD as per RECIST v1.1 or other withdrawal criteria are met.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) in Cohort 1

    Progression-Free Survival (PFS) is defined as the time from the first dose of osimertinib during the adaptive treatment period to the first documentation of disease progression based on investigator assessment according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1, or death from any cause, whichever occurs first.

    Time frame: From initiation of osimertinib in the adaptive therapy period until radiological disease progression or death (up to 33 months).

  2. Time to First ctDNA EGFRm Relapse or Death in Cohort 1

    Time to ctDNA EGFR mutation-positive (EGFRm) relapse is defined as the time from the start of osimertinib treatment in the adaptive therapy period to the first detection of EGFRm in plasma circulating tumour DNA (ctDNA), as assessed by Super ARMS PCR, or death from any cause, whichever occurs first.

    Time frame: From initiation of osimertinib in the adaptive therapy period until ctDNA EGFR mutation relapse or death (up to 33 months)

Secondary outcomes

  1. Overall Survival (OS) in Cohort 1

    Overall Survival (OS) is defined as the time from the first dose of osimertinib in the adaptive therapy period to death from any cause. The 24-month landmark survival rate will be reported.

    Time frame: From initiation of osimertinib in adaptive therapy period until death (up to 33 months)

  2. Cumulative Duration of Chemotherapy Holiday in Cohort 1

    The cumulative duration (in weeks) that participants in Cohort 1 receive osimertinib monotherapy without chemotherapy will be calculated during the adaptive treatment period.

    Time frame: From start of adaptive therapy to disease progression or death (up to 33 months)

  3. Progression-Free Survival (PFS) in Cohort 2

    PFS in Cohort 2 is defined as the time from the start of osimertinib plus pemetrexed maintenance therapy to the first documentation of disease progression per RECIST v1.1 or death from any cause.

    Time frame: From initiation of maintenance therapy to radiological disease progression or death (up to 33 months)

  4. Overall Survival (OS) in Cohort 2

    OS is defined as the time from the first dose of osimertinib plus pemetrexed maintenance therapy to death from any cause. The 24-month landmark survival rate will be reported.

    Time frame: From initiation of maintenance therapy to death (up to 33 months)

  5. Change from Baseline in Health-Related Quality of Life Scores (EORTC QLQ-C30)

    The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) (0-100) will be used to evaluate participants' health-related quality of life. Higher scores on the QLQ-C30 indicate bad life quality of patient. Change from baseline in domain scores will be analyzed. The higher the score is, the worse the quality of life is.

    Time frame: From baseline through end of treatment (up to 33 months)

  6. Change from Baseline in Lung Cancer-Specific Symptoms (EORTC QLQ-LC13)

    The EORTC QLQ-LC13 questionnaire will be used to assess lung cancer-specific symptoms (e.g., cough, dyspnea), with score range 0-100. Higher scores on the QLQ-LC13 indicate worse symptom severity. Changes from baseline will be reported.

    Time frame: From baseline through end of treatment (up to 33 months)

Other outcomes

  1. Frequency of ctDNA EGFRm Relapse During Osimertinib Monotherapy in Cohort 1

    The proportion of participants who experience re-emergence of ctDNA epidermal growth factor receptor mutations (EGFRm) during osimertinib monotherapy in the adaptive therapy period will be reported, as assessed by Super ARMS PCR.

    Time frame: From start of osimertinib monotherapy to disease progression or switch to combination therapy (up to 33 months)

  2. Correlation Between ctDNA EGFRm Relapse and Disease Progression Events

    The temporal and statistical correlation between ctDNA EGFRm re-detection and radiological disease progression events will be analyzed.

    Time frame: From adaptive therapy initiation to progression (up to 33 months)

  3. Acquired Resistance Mechanisms at Disease Progression

    Acquired resistance mechanisms will be assessed using next-generation sequencing (NGS) of plasma (mandatory) and optional tumor tissue samples collected at the time of disease progression. Alterations may include gene mutations, amplifications, and immune markers.

    Time frame: At time of disease progression (up to 33 months)

07

Study locations

1 of 1 sites recruiting
  • Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University
    Shanghai, Shanghai Municipality 200030, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Jan 2029, 40 months after the start.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 40 months is below that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2025
First posted
Jul 10, 2025
StartActual
Sep 23, 2025
Primary completionEst.
Jan 24, 2029
CompletionEst.
Jan 24, 2029
Last update
Nov 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07058519
Collaborators
AstraZeneca
Responsible party
Lu Shun (Professor Chief of Shanghai Lung Cancer Center, Shanghai Chest Hospital) — Principal investigator
First posted
Jul 10, 2025
Start date
Sep 23, 2025
Primary completion
Jan 24, 2029 (estimated)
Completion
Jan 24, 2029 (estimated)
Last update
Nov 26, 2025

Study contacts

Shun Lu, PhD
Contact
shunlu@sjtu.edu.cn
86-21-6282199

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osimertinib

Start the discussion